Beyond BMI: Surgical Readiness in the Age of GLP-1 Therapy
Journal of Orthopaedic Experience & Innovation · 17.10.2026 · 7 (2)
DOI: 10.60118/001c.164818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Orthopaedic Experience & Innovation, online erschienen am 17.10.2026. Verfasst von Thomas Meade und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
GLP-1 receptor agonists like Ozempic and Wegovy are reshaping how healthcare systems approach preoperative optimization. Originally developed for diabetes, these therapies are now widely used for weight reduction. In orthopedics, this shift is transforming patient preparation for major surgeries like Total Knee Arthroplasty (TKA).
Zitieren
APA
Meade, T., MD, & Jazayeri, R. (2026). Beyond BMI: Surgical Readiness in the Age of GLP-1 Therapy. Journal of Orthopaedic Experience & Innovation, 7(2). https://doi.org/10.60118/001c.164818
Vancouver
Meade T, MD, Jazayeri R. Beyond BMI: Surgical Readiness in the Age of GLP-1 Therapy. Journal of Orthopaedic Experience & Innovation. 2026;7(2). doi:10.60118/001c.164818
BibTeX
@article{Meade2026,
author = {Meade, Thomas and MD and Jazayeri, Reza},
title = {Beyond BMI: Surgical Readiness in the Age of GLP-1 Therapy},
journal = {Journal of Orthopaedic Experience & Innovation},
year = {2026},
volume = {7},
number = {2},
doi = {10.60118/001c.164818}
}
EUVIMED